Table 3.
NUCs | Sustained response - no. (%) | Relapse - no. (%) |
---|---|---|
LAM |
11 (24.4) |
2 (10.5) |
ADV |
27 (60.0) |
15 (78.9) |
ETV |
5 (11.1) |
2 (10.5) |
LDT | 2 (4.4) | 0 |
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.
NUCs | Sustained response - no. (%) | Relapse - no. (%) |
---|---|---|
LAM |
11 (24.4) |
2 (10.5) |
ADV |
27 (60.0) |
15 (78.9) |
ETV |
5 (11.1) |
2 (10.5) |
LDT | 2 (4.4) | 0 |
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.